Date: 2015-12-22
Type of information: Initiation of the trial
phase: 1
Announcement: initiation of the trial
Company: Amgen (USA - CA)
Product: AMG 176
Action
mechanism: MCL-1 inhibitor/protein inhibitor. AMG 176 is an inhibitor of induced myeloid leukemia cell differentiation protein MCL-1 (myeloid cell leukemia-1), with potential pro-apoptotic and antineoplastic activities. MCL-1, an anti-apoptotic protein belonging to the Bcl-2 family of proteins, is upregulated in cancer cells and promotes tumor cell survival. Upon administration, AMG 176 binds to and inhibits the activity of MCL-1. This disrupts the formation of MCL-1/Bcl-2-like protein 11 complexes and induces apoptosis in tumor cells.
Disease: relapsed or refractory multiple myeloma
Therapeutic area: Cancer - Oncology
Country: Australia, USA
Trial
details: This first in human study is evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 176 in subjects with relapsed or refractory multiple myeloma. At least one dose level of AMG 176 will achieve acceptable safety and tolerability in subjects with relapsed or refractory multiple myeloma. (NCT02675452)
Latest
news: * On December 22, 2015, a Phase I trial sponsored by Amgen was published on the NIH website ClinicalTrials.gov for AMG 176 and is currently recruiting participants.
